Renal Cell Carcinoma Market Report 2026

The renal cell carcinoma market size has grown steadily in recent years. It will grow from $4.96 billion in 2025 to $5.13 billion in 2026 at a compound annual growth rate (CAGR) of 3.5%. The growth in the historic period can be attributed to increasing incidence of kidney cancer, wider availability of imaging-based diagnostics, adoption of surgical nephrectomy procedures, expansion of oncology treatment centers, improved survival rates through early diagnosis.

The renal cell carcinoma market size is expected to see steady growth in the next few years. It will grow to $6.09 billion in 2030 at a compound annual growth rate (CAGR) of 4.4%. The growth in the forecast period can be attributed to increasing development of novel targeted therapies, rising use of immunotherapy combinations, expansion of precision oncology programs, growing adoption of biomarker-guided treatment selection, increasing investment in oncology research and trials. Major trends in the forecast period include increasing adoption of targeted cancer therapies, rising use of combination treatment regimens, growing focus on early and accurate diagnosis, expansion of minimally invasive surgical approaches, enhanced emphasis on personalized oncology care.

The increasing size of the geriatric population is anticipated to drive the growth of the renal cell carcinoma market in the coming years. The geriatric population includes older adults, typically aged 65 years and above, who often have distinct healthcare and social needs. The expansion of the elderly population is largely attributed to advancements in healthcare, improved nutrition, and longer life expectancy. Renal cell carcinoma (RCC) occurs more frequently among older individuals, underscoring the need for age-specific screening programs and treatment approaches tailored to this population. For example, in January 2024, according to a report released by the Population Reference Bureau, a US-based nonprofit organization that collects demographic data for research and academic use, the number of Americans aged 65 and above is projected to increase from 58 million in 2022 to 82 million by 2050, representing a 47% rise. Therefore, the growth of the geriatric population is fueling the expansion of the renal cell carcinoma market.

Major companies operating in the renal cell carcinoma market are emphasizing the development of technologically advanced solutions, such as artificial intelligence (AI)-powered tools for kidney biopsy analysis, to improve diagnostic precision, streamline clinical workflows, and enhance patient outcomes. AI-powered kidney biopsy analysis solutions utilize machine learning algorithms and computer vision techniques to support pathologists and nephrologists in the evaluation of renal tissue samples, aiming to increase accuracy, consistency, and efficiency in diagnosis and disease assessment. For instance, in March 2024, Aiosyn, a Netherlands-based software company, introduced the NephroPath platform, an advanced AI-driven solution for kidney biopsy analysis. The NephroPath platform employs computational pathology algorithms to assess histological biomarkers in kidney biopsies, including tissue classification, measurement of interstitial fibrosis, and accurate counting and evaluation of glomeruli. This AI-enabled approach delivers consistent, detailed, and reproducible scoring of renal pathology biomarkers, helping to overcome the limitations of traditional manual assessment methods and reduce observer variability.

In October 2024, Arcus Biosciences, a US-based biotechnology company, entered into a partnership with AstraZeneca plc to evaluate the combination of casdatifan (AB521) and volrustomig in patients with clear cell renal cell carcinoma (ccRCC). This collaboration seeks to advance ccRCC treatment by developing a novel combination therapy, leveraging the expertise of both organizations to accelerate clinical development and improve patient outcomes. AstraZeneca plc is a UK-based pharmaceutical company focused on oncology research and treatment.

Major companies operating in the renal cell carcinoma market are Pfizer Inc., Johnson And Johnson, F Hoffmann La Roche Ltd, Merck And Co Inc, Bayer AG, Bristol Myers Squibb Company, AstraZeneca Plc, Novartis AG, GSK plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Viatris Inc, Astellas Pharma Inc., Eisai Co Ltd, Sun Pharmaceutical Industries Ltd, Ipsen Pharma, Cipla Inc., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Exelixis Inc., Nektar Therapeutics, BeiGene Ltd, Incyte Corporation, Regeneron Pharmaceuticals Inc., AbbVie Inc.

North America was the largest region in the renal cell carcinoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the renal cell carcinoma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the renal cell carcinoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the renal cell carcinoma market by increasing costs of imported oncology drugs, diagnostic imaging equipment, surgical instruments, and targeted therapy components. Hospitals and specialty cancer centers in North America and Europe are most affected due to dependence on imported pharmaceuticals and advanced medical devices, while Asia-Pacific faces cost pressures on exported oncology products. These tariffs are raising treatment costs and affecting therapy accessibility. However, they are also encouraging domestic drug manufacturing, regional clinical research investments, and localized production of oncology therapeutics.

The renal cell carcinoma market research report is one of a series of new reports that provides renal cell carcinoma market statistics, including renal cell carcinoma industry global market size, regional shares, competitors with a renal cell carcinoma market share, detailed renal cell carcinoma market segments, market trends and opportunities, and any further data you may need to thrive in the renal cell carcinoma industry. This renal cell carcinoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Renal cell carcinoma (RCC) is a type of kidney cancer that develops in the renal tubules, which are responsible for filtering waste and producing urine. The disease begins when kidney cells become abnormal and proliferate uncontrollably, leading to tumor formation. This abnormal growth can impair normal kidney function, including blood filtration and urine production.

The main types of renal cell carcinoma include clear cell renal cell carcinoma (RCC), papillary RCC, and chromophobe RCC. Clear cell RCC is the most common form of kidney cancer and originates in the renal tubules involved in blood filtration. Under microscopic examination, these cancer cells appear clear or pale due to the accumulation of lipids and carbohydrates. Diagnosis is carried out using methods such as urine tests, blood tests, computed tomography (CT) scans, ultrasound, nephrectomy, and biopsy. Treatment options include surgery, targeted therapy, chemotherapy, ablation, medications, and other approaches, and are provided across settings such as hospitals, specialty clinics, homecare, and other end-user environments.

The renal cell carcinoma market consists of revenues earned by entities by providing services such as CT scans, ultrasounds, chemotherapy and targeted therapy, immunotherapy, and supportive care and counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The renal cell carcinoma market also includes sales of needle biopsy systems, laser ablation devices, biopsy trays and kits, and biopsy specimen containers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.